The American Academy of Dermatology Association (AAD) announced that the draft clinical practice guidelines for the management of atopic dermatitis (AD) with recently FDA-approved therapies are now available for review and comment by all AAD members.
These guidelines offer evidence-based recommendations on the efficacy, effectiveness, and potential adverse effects of AD treatment. The development of these guidelines followed a rigorous and systematic approach, with recommendations crafted by a guideline work group comprised of experts in AD management from various clinical settings, methodologists, and a patient representative.
As part of AAD’s development process, they invite members to review and give feedback. Interested members are encouraged to submit their comments here by February 17, 2025. Your input is invaluable in shaping the future of atopic dermatitis management.
Copyright © 2025 Guideline Central, All Rights Reserved.